Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Vocal Intonation Therapy and Therapeutic Singing for the Improvement of Respiratory Function in Patients with Stage I-III Lung Cancer

Trial Status: administratively complete

This clinical trial examines the short-term impact of vocal intonation therapy (VIT) and therapeutic singing (TS) on respiratory function in patients with stage I-III lung cancer. Music therapy interventions such as oral motor and respiratory exercises (OMREX) and VIT have contributed to significant improvements in respiratory function and respiratory neural plasticity (persistent change seen in the inflamed airway based on prior experience and injury) in patients with cervical spinal cord injury. Additionally, older patients with respiratory disease have shown improvements in inspiratory (act of breathing in) muscle strength following group singing experiences. VIT is a neurologic music therapy technique that incorporates vocal and breathing exercises to promote the rehabilitation of various aspects of the voice apparatus such as voice dynamics and breath control. TS is a neurologic music therapy technique that utilizes singing activities to address a variety of therapeutic outcomes including respiratory control and vital capacity. Additionally, TS can serve as a form of physical exercise to promote respiratory strengthening and endurance. Information gathered from this study may help researchers determine whether VIT and TS may improve respiratory function in patients with stage I-III lung cancer.